Company: PTPI
Filing Date: 2025-03-18
Form Type: DEF 14A
Source: 0001104659-25-025104
Chunk: 32

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-18
Form: DEF 14A
Chunk 32
---
 of the Issuance Proposal, existing stockholders will suffer dilution in their ownership interests in the future as a result of
the potential issuance of shares of Common Stock upon exercise of the Series Warrants. Assuming the full exercise of the Series Warrants
at the floor price of $0.0586, and assuming the Series B Warrants are exercised on a Zero Exercise Price basis, an aggregate of approximately
1,064,846,416.38 additional shares of Common Stock will be outstanding and the ownership interest of our existing stockholders would be
correspondingly reduced.

The number of shares of Common Stock described above does not give
effect to potential additional shares underlying the Series Warrants that may be issuable after effectiveness of the Stockholder
Approval upon the adjustments of the exercise price of the Series Warrants pursuant to their terms. The sale into the public market
of these shares also could materially and adversely affect the market price of our Common Stock.

Consequences of Not Approving the Issuance Proposal

After extensive efforts to raise capital on more favorable terms, we
believed that the Offering was the only viable financing alternative available to us at the time. Unless we obtain stockholder approval
for the Issuance Proposal, we will be required to incur additional costs in order to hold additional stockholder meetings to seek such
approval as is required under the Purchase Agreement. Further, until such time as we receive the Stockholder Approval, we will not be
able to issue 20% or more of our outstanding shares of Common Stock to the Series Warrant holders in connection with the Offering. If,
despite the Company’s reasonable best efforts the Stockholder Approval is not obtained after such subsequent stockholder meetings,
the Company shall cause an additional stockholder meeting to be held every ninety (90) days thereafter. Holding such additional stockholder
meetings can be time-consuming, divert management’s attention and resources, and cause us to incur significant expenses.

<div align='center'>20</div>

Interest of Certain Persons in Matters to Be Acted Upon

When you consider our
Board’s recommendation to vote in favor of this proposal, you should be aware that our directors and executive officers and
existing stockholders may have interests that may be different from, or in addition to, the interests of other of our stockholders.
In particular, Iroquois Capital Investment Group, LLC (“ICIG”), which beneficially owns more than 5% of our voting
securities, and its affiliate Iroquois